Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2025

Q3 2025 biggest moves
  • OSCROSCR

    Oscar Health

    Sold out

    was 4.5% of portfolio

  • CNCCNC

    Centene

    2.8× the shares

    now 4.9% of portfolio

  • IONSIONS

    Ionis Pharmaceuticals

    New

    2.0% of portfolio

  • BMYBMY

    Bristol-Myers Squibb

    New

    1.6% of portfolio

136 changes in all

Top Holdings152 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

18M$1.6B23.8%——
17 qtrssince 2021-Q3
Unchanged
0
CNC

Centene Corporation

9M$322.8M4.9%$46.26-22.87%
24 qtrssince 2019-Q4
Increased
92
MRUS
MRUSDelisted

MERUS N V

3M$286.9M4.4%——
16 qtrssince 2021-Q4
Decreased
0
VTRS

Viatris Inc.

24.1M$238.6M3.6%$11.15-14.26%
20 qtrssince 2020-Q4
Increased
56
UTHR

United Therapeutics Corporation

425,993$178.6M2.7%$298.00+40.67%
3 qtrssince 2025-Q1
Decreased
0
RVMD

Revolution Medicines, Inc.

3.7M$170.5M2.6%$29.54+58.11%
23 qtrssince 2020-Q1
Increased
56
INDV
INDVDelisted

INDIVIOR PLC

7M$168.5M2.6%$8.28+125.83%
5 qtrssince 2024-Q3
Decreased
0
70M$168.2M2.6%——
6 qtrssince 2024-Q2
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.2M$166.3M2.5%$107.87+30.14%
19 qtrssince 2021-Q1
Increased
53
COGT

Cogent Biosciences, Inc.

9.1M$130M2.0%$12.67+13.35%
20 qtrssince 2020-Q4
Increased
77
IONS

Ionis Pharmaceuticals, Inc.

2M$129.5M2.0%$65.420.00%
1 qtr
New
69
NAMS

NewAmsterdam Pharma Company N.V.

4.3M$121.3M1.9%$23.65+20.28%
7 qtrssince 2024-Q1
Decreased
0
VERA

Vera Therapeutics, Inc.

3.6M$105.8M1.6%$24.14+20.40%
3 qtrssince 2025-Q1
Increased
51
BMY

Bristol-Myers Squibb Company

2.3M$105.4M1.6%$42.59+21.24%
1 qtr
New
68
AHCO

AdaptHealth Corp.

11.5M$102.7M1.6%$16.65-46.26%
24 qtrssince 2019-Q4
Increased
54
LRMR

Larimar Therapeutics, Inc.

30.6M$98.9M1.5%$5.59-42.27%
22 qtrssince 2020-Q2
Increased
64
BKD

Brookdale Senior Living Inc.

11.6M$98.6M1.5%$4.41+92.04%
24 qtrssince 2019-Q4
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

5M$98M1.5%——
13 qtrssince 2022-Q3
Increased
71
LEGN
LEGN
ADR

Legend Biotech Corporation

3M$96.6M1.5%$33.84-3.65%
4 qtrssince 2024-Q4
Unchanged
0
BCRX

BioCryst Pharmaceuticals, Inc.

12.2M$92.4M1.4%$7.23+4.97%
11 qtrssince 2023-Q1
Increased
76
$6.6B
AUM
152
Positions
Q3 2025
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2024-Q2$6,010,510,6294.56571927342%
2024-Q3$6,692,805,83111.3517011135%
2024-Q4$5,280,006,191-21.1092279632%
2025-Q1$5,064,779,427-4.07625969013%
2025-Q2$5,509,809,2648.78675652937%
2025-Q3$6,550,740,15118.8923216236%
Activity profile
$ moved · Q3'25
New26%Increased30%Decreased17%Exited27%
Composition
Equity vs derivatives
Equity>99%Puts<1%Calls0%
Holding period
Avg 2.2 years
<1Q16%1-4Q11%1-2Y25%2Y+47%

Deerfield Management Company, L.P. manages $6.6B across 152 positions as of Q3 2025. Top holdings: NUVL (23.8%), CNC (4.9%), MRUS (4.4%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$7B
NUVL23.75%
CNC4.93%
MRUS4.38%
VTRS3.64%
UTHR2.73%
RVMD2.60%
INDV2.57%
MIRUM PHARMA2.57%
NBIX2.54%
COGT1.98%
Other1.98%

Portfolio allocation by GICS sector

Sectors6
Healthcare99.33%
Real Estate0.41%
Unknown0.10%
Financial Services0.08%
Consumer Defensive0.07%
Consumer Cyclical0.01%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used